Crossmark

Prospective observational study to assess the feasibility and safety of appropriate <i>Plasmodium vivax</i> radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand

Crossref DOI link: https://doi.org/10.1136/bmjgh-2024-016720

Published Online: 2025-04-24

Published Print: 2025-04

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Sudathip, Prayuth https://orcid.org/0009-0004-1685-2141
Khantikul, Nardlada

Saejeng, Aungkana

Duparc, Stephan

Grewal Daumerie, Penny

Lynch, Caroline

Jambert, Elodie

Viboonsanti, Saowanee

Areechokchai, Darin

Kanjanasuwan, Jerdsuda

Thong-ard, Thannika

Kowsurat, Panupong

Borghini-Fuhrer, Isabelle

Padungtod, Chantana
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05753150 at ClinicalTrials.gov

Documents that mention this clinical trial

Prospective observational study to assess the feasibility and safety of appropriate <i>Plasmodium vivax</i> radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand
https://doi.org/10.1136/bmjgh-2024-016720
Funding

Funding for this research was provided by:

Bill & Melinda Gates Foundation (OPP1059029)

MMV Medicines for Malaria Venture
License Information

License valid from 2025-04-24

Document is current

Any future updates will be listed below